

erythropoietin, a tissue plasminogen activator, a human growth factor, an antithrombin III, an insulin, a prolactin, and an .alpha.-1-antitrypsin.

128. (Previously Presented) The method of claim 92, wherein said second non-human differentiated somatic cell or cell-lines are fibroblasts.

129. (Previously Presented) The method of claim 128, wherein said fibroblasts are primary fibroblasts.

130. (Previously Presented) The method of claim 128, wherein said fibroblasts are primary derived fibroblasts.

REMARKS

Applicant has amended claim 97 to correct a typographical error.

The Examiner required restriction between Groups I, II, and III. Applicant hereby provisionally elects claims Group I, 92-104, 106-109, 111-115, 117-130 for continued examination.

The Examiner further required a species election, determining that the cell type used (claims 118, 128-130), the species of animal made (claim 103), and the protein expressed (claim 127) are patentably distinct species. Applicants elect for initial examination primary fibroblasts for the cell type, caprine for the animal, and antithrombin III for the protein. Claims 92-104, 106-109, 111-115, 118-129 read on the cell species. Claims 92-104, 106-109, 111-115, 117-130 read on the animal species. Claims 92-104, 106-109, 111-115, 117-130 read on the protein species.

Applicant notes that, upon a determination that the species are allowable, any nonexamined species claims will be rejoined and examined. *See* MPEP §808.01(a).

Dated: July 24, 2006

Respectfully submitted,

By 

Michael T. Siekman

Registration No.: 36,276

WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
(617) 646-8000